For Immediate Release
When: News media is invited to attend the presentation by Lankenau Institute for Medical Research (LIMR) researcher on “’IDO pathways” on Friday, April 17 from11:30 am – Noon.
What: The 4th International Conference on Immunochemotherapy, hosted this year by the Lankenau Institute for Medical Research (LIMR), part of Main Line Health, will bring together leading researchers in the quest to improve cancer therapy by using a patient’s own immune system. You can read more about the conference here: https://www.abcam.com/index.html?pageconfig=resource&rid=16398
Who: This event is being co-chaired by LIMR President George Prendergast, PhD, along with fellow pioneers in the field of immunochemotherapy Guido Kroemer, MD, PhD, and Laurence Zitvogel, MD, PhD, of the Gustave Roussy Cancer Center in Paris, and Jeffrey Weber, MD, PhD, of the Moffitt Cancer Center in Tampa. In addition, the 2-day event will feature presentations by researchers from major cancer centers and research institutes across the globe.
Why: Dr. Prendergast will discuss research that began more than 10 years ago at LIMR on so-called “IDO1 inhibitors.” These drugs target an enzyme that tumors “turn on” to suppress the immune system—the research that began at LIMR has since been acquired by several other major pharmaceutical companies… if and when these IDO inhibitors offer a cure for cancer, Philadelphia will be a part of that story.
Where: The Lankenau Institute for Medical Research (LIMR), 100 East Lancaster Avenue, Wynnewood, PA 19096
